Literature DB >> 6849796

Promotion mechanism of phenobarbital and partial hepatectomy in DENA hepatocarcinogenesis cell kinetics effect.

H Barbason, C Rassenfosse, E H Betz.   

Abstract

Diethylnitrosamine (DENA, 10 mg kg-1 per day) was fed to rats for 2, 4 and 6 weeks. One week after the cessation of DENA, animals were submitted either to partial hepatectomy or to phenobarbital administration. Partial hepatectomy did not promote neoplastic transformation, except after a 6-week DENA treatment. A minimum of phenobarbital was required to reach a significant promoting effect in DENA carcinogenesis. A too-limited treatment was ineffectual but could be compensated for by prolonged DENA administration. The phenobarbital treatment became unnecessary when neoplastic nodules were present. Phenobarbital continuously given after the carcinogen administration promoted neoplastic transformation even after a subcarcinogenic DENA treatment (2 weeks). It accelerated the pathological evolution and increased the tumour incidence. In these conditions, phenobarbital increased the proliferation advantage of preneoplastic cells over normal cells. In the different experimental modalities, the promoting effect was associated with the induction of chronic cell proliferation, the inhibition of the rapid response to the 2/3 partial hepatectomy and the mitotic circadian rhythm normally present during liver regeneration. It is concluded that the promotion mechanism could consist in disturbing the mitotic control in order to maintain, for a long time, a chronic low level of cell proliferation permitting the selective growth of preneoplastic cells and their subsequent transformation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849796      PMCID: PMC2011340          DOI: 10.1038/bjc.1983.82

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Foci of altered liver cells induced by a single dose of diethylnitrosamine and partial hepatectomy: their contribution to hepatocarcinogenesis in the rat.

Authors:  E Scherer; P Emmelot
Journal:  Eur J Cancer       Date:  1975-03       Impact factor: 9.162

2.  THE INFLUENCE OF AGE UPON THE INCORPORATION OF THYMIDINE-2-C14 INTO THE DNA OF REGENERATING RAT LIVER.

Authors:  N L BUCHER; M N SWAFFIELD; J F DITROIA
Journal:  Cancer Res       Date:  1964-04       Impact factor: 12.701

3.  Report of a workshop on classification of specific hepatocellular lesions in rats.

Authors:  R A Squire; M H Levitt
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

4.  Modification of diethylnitrosamine liver carcinogenesis with phenobarbital but not with immunosuppression.

Authors:  J H Weisburger; R M Madison; J M Ward; C Viguera; E K Weisburger
Journal:  J Natl Cancer Inst       Date:  1975-05       Impact factor: 13.506

5.  Liver cell responses to the carcinogen 3'-methyl-4-dimethylaminoazobenzene.

Authors:  P E Hughes
Journal:  Chem Biol Interact       Date:  1970-02       Impact factor: 5.192

6.  Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene.

Authors:  C Peraino; R J Fry; E Staffeldt
Journal:  Cancer Res       Date:  1971-10       Impact factor: 12.701

7.  The stimulation of liver growth and demethylase activity following phenobarbital treatment.

Authors:  T S Argyris; D R Magnus
Journal:  Dev Biol       Date:  1968-02       Impact factor: 3.582

8.  The effect of L-asparaginase on mitotic activity during N-2-fluorenylacetamide hepatocarcinogenesis: subpopulations of nodular cells.

Authors:  F F Becker; K M Klein
Journal:  Cancer Res       Date:  1971-02       Impact factor: 12.701

9.  Additive effects of phenobarbital and high protein diet on liver growth in immature male rats.

Authors:  T S Argyris
Journal:  Dev Biol       Date:  1971-06       Impact factor: 3.582

10.  Comparative enhancing effects of phenobarbital, amobarbital, diphenylhydantoin, and dichlorodiphenyltrichloroethane on 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat.

Authors:  C Peraino; R J Fry; E Staffeldt; J P Christopher
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

View more
  8 in total

Review 1.  Differential growth: from carcinogenesis to liver repopulation.

Authors:  E Laconi
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats.

Authors:  I Shimizu; M Yasuda; Y Mizobuchi; Y R Ma; F Liu; M Shiba; T Horie; S Ito
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

3.  Liver tumor promotion: effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-beta 1 expression.

Authors:  R L Jirtle; S A Meyer
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

4.  O4-ethyldeoxythymidine, but not O6-ethyldeoxyguanosine, accumulates in hepatocyte DNA of rats exposed continuously to diethylnitrosamine.

Authors:  J A Swenberg; M C Dyroff; M A Bedell; J A Popp; N Huh; U Kirstein; M F Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

5.  Effect of phenobarbital on hepatic cell proliferation and apoptosis in mice deficient in the p50 subunit of NF-kappaB.

Authors:  Job C Tharappel; Brett T Spear; Howard P Glauert
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-26       Impact factor: 4.219

6.  Chronic mitoinhibition during promotion of hepatocarcinogenesis.

Authors:  E Laconi; P M Rao; S Rajalakshmi; P Pani; D S Sarma
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

7.  Influence of liver tumor promoters and structurally related chemicals on survival of normal adult rat hepatocytes in primary culture.

Authors:  M Miyazaki; L Bai; J Sato
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

8.  Cell population kinetics and ploidy rate of early focal lesions during hepatocarcinogenesis in the rat.

Authors:  P Castelain; A Deleener; M Kirsch-Volders; H Barbason
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.